Out-Licensing
In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- January 21, 2011 The art of microRNA research Circulation Research
- October 18, 2010 Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice The Journal of Clinical Investigation
- August 13, 2010 The road toward microRNA therapeutics The International Journal of Biochemistry & Cell Biology
- August 11, 2010 MicroRNA regulation as a therapeutic strategy for cardiovascular disease. Current Drug Targets
- August 1, 2010 Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta Genes & Development
- June 16, 2010 miRNAs as therapeutic targets in ischemic heart disease Journal of Cardiovascular Translational Research
- January 12, 2010 Therapeutic Advances in microRNA Targeting Journal of Cardiovascular Pharmacology
- December 11, 2009 MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice Science
- November 12, 2009 A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance Developmental Cell
- September 15, 2009 MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury Genes & Development